New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
11:08 EDTTROVTrovagene says diagnostic platform demonstrates ability to monitor mutations
Clinical study results presented at the American Association for Cancer Research Annual Meeting demonstrate the ability of Trovagene's molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients, the company said. Of the 33 patients enrolled in the study, Trovagene's BRAF V600E oncogene mutation assay was able to identify the mutation in 29 patients, or 88%, at any time point during the study, demonstrating a high level of concordance with tissue biopsy. In addition, 25 of the 33 patients, or 76%, were positively identified for the mutation with their first urine sample. Mark Erlander, Ph.D., chief scientific officer of Trovagene, stated, "The concordance shown between our platform and tissue biopsy in this study are encouraging, especially when we consider that different patients will show response to treatments at different times."
News For TROV From The Last 14 Days
Check below for free stories on TROV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
11:13 EDTTROVTrovagene data increases IP monetization potential, says Maxim
Subscribe for More Information
08:10 EDTTROVTrovagene presents urine-based HPV assay clinical results
Trovagene announced that results from two independent clinical studies were presented at the 29th International Papillomavirus Conference. Results from both pilot studies consistently demonstrated that the company's urine-based assay for the detection of high-risk HPV had high sensitivity for identifying women with high grade cervical intraepithelial neoplasia. Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing. In an oral presentation entitled "Evaluation of Two Urine-Based HPV Assays In Comparison to Cervical HPV Detection and High-Grade CIN Among Women Attending a Colposcopy Clinic," results from a population-based National Cancer Institute study, conducted at the University of Oklahoma Health Sciences Center, were released. A second presentation entitled "A Comparison of Urine Collection Times for the Detection of High-Risk HPV Infection in Women" included results from a study conducted at University of North Carolina, Chapel Hill. The company said, "The positive study results presented at the IPV Conference are very encouraging as we continue to conduct clinical studies to evaluate the performance of our urine-based high-risk HPV assay as a viable alternative to conventional HPV testing from a cervical specimen. A significantly larger, blinded study which compares sensitivity of detecting high-risk HPV in patients with CIN2/3 in urine versus cervical samples is ongoing and results will be reported by 1Q15."
August 18, 2014
07:59 EDTTROVTrovagene current levels offer buying opportunity, says Maxim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use